Antihepatoma activity of multifunctional polymeric nanoparticles via inhibition of microtubules and tyrosine kinases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel R , Ma J , Zou Z , Jemal A . Cancer statistics. CA Cancer J. Clin. 64(1), 9–29 (2014).
  MedlineGoogle Scholar
• 2. Yang JD , Roberts LR . Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 7(8), 448–458 (2010).
  MedlineGoogle Scholar
• 3. Terry K , Copur MS . Molecular targeted therapy of hepatocellular carcinoma. J. Cancer Ther. 4(2), 426–439 (2013).
  Google Scholar
• 4. Choe MS , Chen Z , Klass CM , Zhang X , Shin DM . Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13(10), 3015–3023 (2007).
  Medline CASGoogle Scholar
• 5. Herbst RS , Khuri FR . Mode of action of docetaxel – a basis for combination with novel anticancer agents. Cancer Treat. Rev. 29(5), 407–415 (2003).
  Medline CASGoogle Scholar
• 6. Seligmann J , Twelves C . Tubulin: an example of targeted chemotherapy. Future Med. Chem. 5(3), 339–352 (2013). •• Provides information on clinically used microtubule-targeting agents.
  Medline CASGoogle Scholar
• 7. Dumontet C , Jordan MA . Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9(10), 790–803 (2010). • A comprehensive review of microtubule-binding agents.
  Medline CASGoogle Scholar
• 8. Zhang J , Yang PL , Gray NS . Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer. 9(1), 28–39 (2009). • A broad overview of small-molecule kinase inhibitors in cancer.
  MedlineGoogle Scholar
• 9. Wilhelm S , Carter C , Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5(10), 835–844 (2006).
  Medline CASGoogle Scholar
• 10. Baker J , Ajani J , Scotté F et al. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs. 13(1), 49–59 (2009).
  MedlineGoogle Scholar
• 11. Montero A , Fossella F , Hortobagyi G , Valero V . Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 6(4), 229–239 (2005).
  Medline CASGoogle Scholar
• 12. Baker SD , Zhao M , Lee CK et al. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin. Cancer Res. 10(6), 1976–1983 (2004).
  Medline CASGoogle Scholar
• 13. Morabito A , De Maio E , Di Maio M , Normanno N , Perrone F . Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 11(7), 753–764 (2006).
  Medline CASGoogle Scholar
• 14. Wilhelm SM , Adnane L , Newell P , Villanueva A , Llovet JM , Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129–3140 (2008).
  Medline CASGoogle Scholar
• 15. Almhanna K , Philip PA . Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco. Targets Ther. 2, 261–267 (2009).
  Medline CASGoogle Scholar
• 16. Lacouture ME , Reilly LM , Gerami P , Guitart J . Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann. Oncol. 19(11), 1955–1961 (2008).
  Medline CASGoogle Scholar
• 17. Carr BI , Carroll S , Muszbek N , Gondek K . Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J. Gastroenterol. Hepatol. 25(11), 1739–1746 (2010).
  MedlineGoogle Scholar
• 18. Shin HC , Alani AW , Rao DA , Rockich NC , Kwon GS . Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Rel. 140(3), 294–300 (2009).
  Medline CASGoogle Scholar
• 19. Liu Y , Feng L , Liu T et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale 6(6), 3231–3242 (2014).
  Medline CASGoogle Scholar
• 20. Avgoustakis K . Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv. 1(4), 321–333 (2004).
  Medline CASGoogle Scholar
• 21. Kamaly N , Xiao Z , Valencia PM , Radovic-Moreno AF , Farokhzad OC . Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41(7), 2971–3010 (2012). •• Provides insights into the design and development of polymeric therapeutic nanoparticles.
  Medline CASGoogle Scholar
• 22. ClinicalTrials.gov (2015). https://clinicaltrials.gov/ct2/show/NCT01792479
  Google Scholar
• 23. Musumeci T , Ventura CA , Giannone I et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int. J. Pharm. 325(1–2), 172–179 (2006).
  Medline CASGoogle Scholar
• 24. Liu Y , Li K , Pan J , Liu B , Feng SS . Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 31(2), 330–338 (2010).
  Medline CASGoogle Scholar
• 25. Agrawal R , Shanavas A , Yadav S , Aslam M , Bahadur D , Srivastava R . Polyelectrolyte coated polymeric nanoparticles for controlled release of docetaxel. J. Biomed. Nanotechnol. 8(1), 19–28 (2012).
  Medline CASGoogle Scholar
• 26. Roy A , Murakami M , Ernsting MJ , Hoang B , Undzys E , Li SD . Carboxymethylcellulose-based and docetaxel-loaded nanoparticles circumvent P-glycoprotein-mediated multidrug resistance. Mol. Pharm. 11(8), 2592–2599 (2014).
  Medline CASGoogle Scholar
• 27. Zhang X , Yang Y , Liang X et al. Enhancing therapeutic effects of docetaxel-loaded dendritic copolymer nanoparticles by co-treatment with autophagy inhibitor on breast cancer. Theranostics 4(11), 1085–1095 (2014).
  MedlineGoogle Scholar
• 28. Hrkach J , Von Hoff D , Mukkaram Ali M et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4(128), 128–139 (2012). •• Illustrates the importance of clinical translation of a PSMA-targeted docetaxel nanoparticle.
  Google Scholar
• 29. Zhang L , Gong F , Zhang F , Ma J , Zhang P , Shen J . Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro. Int. J. Nanomed. 8, 1517–1524 (2013).
  MedlineGoogle Scholar
• 30. Poojari R , Kini S , Srivastava R , Panda D . Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells. Colloids Surf. B. 143, 131–138 (2016). •• Demonstrates the anticancer potential of layer-by-layer assembled polyelectrolytes-based sorafenib nanoparticles against oral cancer.
  Medline CASGoogle Scholar
• 31. Wu X , Liu H , Liu J et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 21(1), 41–46 (2003). •• Illustrates the importance of quantum dots-based probes in cellular imaging.
  Medline CASGoogle Scholar
• 32. Saran AD , Sadawana MM , Srivastava R , Bellare JR . An optimized quantum dot-ligand system for biosensing applications: evaluation as a glucose biosensor. Colloids Surf. A: Physicochem. Eng. Asp. 384(1–3), 393–400 (2011).
  CASGoogle Scholar
• 33. May A , Bhaumik S , Gambhir SS , Zhan C , Yazdanfar S . Whole-body, real-time preclinical imaging of quantum dot fluorescence with time-gated detection. J. Biomed. Opt. 14(6), 060504 (2009).
  MedlineGoogle Scholar
• 34. Zhang LW , Monteiro-Riviere NA . Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci. 110(1), 38–55 (2009).
  Google Scholar
• 35. Muthu MS , Kulkarni SA , Raju A , Feng SS . Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials 33(12), 3494–3501 (2012).
  Medline CASGoogle Scholar
• 36. Dubertret B , Skourides P , Norris DJ , Noireaux V , Brivanlou AH , Libchaber A . In vivo imaging of quantum dots encapsulated in phospholipid micelles . Science 298 (5599), 1759–1762 (2002).
  Google Scholar
• 37. Poojari R , Kini S , Srivastava R , Panda D . A chimeric cetuximab-functionalized corona as a potent delivery system for microtubule-destabilizing nanocomplexes to hepatocellular carcinoma cells: a focus on EGFR and tubulin intracellular dynamics. Mol. Pharm. 12(11), 3908–3923 (2015).
  Medline CASGoogle Scholar
• 38. Vichai V , Kirtikara K . Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1(3), 1112–1116 (2006).
  Medline CASGoogle Scholar
• 39. Hura N , Sawant AV , Kumari A , Guchhait SK , Panda D . Combretastatin-inspired heterocycles as antitubulin anticancer agents. ACS Omega. 3, 9754–9769 (2018).
  Medline CASGoogle Scholar
• 40. Franken NA , Rodermond HM , Stap J , Haveman J , Van Bree C . Clonogenic assay of cells in vitro . Nat. Protoc. 1(5), 2315–2319 (2006).
  Medline CASGoogle Scholar
• 41. Munshi A , Hobbs M , Meyn RE . In: Chemosensitivity: In Vitro Assays (Volume 1). Blumenthal RD (Ed.). Humana Press, NJ, USA, Chapter 2, 21–28 (2005).
  Google Scholar
• 42. Arnaoutova I , Kleinman HK . In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract . Nat. Protoc. 5(4), 628–635 (2010).
  Medline CASGoogle Scholar
• 43. Sun D , Liu Y , Yu Q , Zhou Y , Zhang R , Chen X . The effects of luminescent ruthenium(II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials 34(1), 171–80 (2013).
  Medline CASGoogle Scholar
• 44. Sonntag R , Gassler N , Bangen JM , Trautwein C , Liedtke C . Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo . Cell Death Dis. 5, e1030 (2014).
  Medline CASGoogle Scholar
• 45. Xiong YQ , Sun HC , Zhang W et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin. Cancer Res. 15(15), 4838–4846 (2009).
  Medline CASGoogle Scholar
• 46. Abou-Alfa GK , Schwartz L , Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293–4300 (2006).
  Medline CASGoogle Scholar
• 47. Schmidt CM , McKillop IH , Cahill PA , Sitzmann JV . Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236(1), 54–58 (1997).
  Medline CASGoogle Scholar
• 48. Xie B , Wang DH , Spechler SJ . Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig. Dis. Sci. 57(5), 1122–1129 (2012).
  Medline CASGoogle Scholar
• 49. Huynh H , Do PT , Nguyen TH et al. Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma. Int. J. Oncol. 25(6), 1839–1847 (2004).
  Medline CASGoogle Scholar
• 50. Bisteau X , Caldez MJ , Kaldis P . The complex relationship between liver cancer and the cell cycle: a story of multiple regulations. Cancers (Basel) 6(1), 79–111 (2014).
  MedlineGoogle Scholar
• 51. Poojari R , Panda D , Srivastava R . Multifunctional polymeric nanocarrier. Indian Patent Granted No. 317866 (2019).
  Google Scholar
• 52. Poojari R , Srivastava R , Panda D . Molecular intersection of a 3-in-1 nanomedicine targeting microtubules, ERK tyrosine kinases with profound nuclear modulations, and quantum imaging for hepatocellular carcinoma therapy. Presented at: Proceedings of the American Association for Cancer Research Annual Meeting. Washington, DC (1–5 April 2017).
  Google Scholar